Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
about
Pharmacological interventions for improving respiratory function in amyotrophic lateral sclerosisCOPD exacerbations. 4: PreventionInfluencing the decline of lung function in COPD: use of pharmacotherapy.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in CaucasiansInhalation of beta 2 agonists impairs the clearance of nontypable Haemophilus influenzae from the murine respiratory tract.Beta-agonist intrinsic efficacy: measurement and clinical significance.Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.Advances in the management of chronic obstructive pulmonary disease.Long-acting inhaled beta 2-agonists for stable COPD.Formoterol: a review of its use in chronic obstructive pulmonary disease.Pharmacological approaches to stable chronic obstructive pulmonary disease.COPD exacerbations.5: management.Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbationsThe role of bronchodilator treatment in the prevention of exacerbations of COPD.Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.Inhaled therapy for stable chronic obstructive pulmonary disease.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.Pharmacological treatment of chronic obstructive pulmonary disease.Budesonide-formoterol (inhalation powder) in the treatment of COPD.Formoterol in the management of chronic obstructive pulmonary disease.Similarities and differences in the autonomic control of airway and urinary bladder smooth muscleProfile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDEffects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease.Pre-operative pulmonary assessment for patients with hip fracture.Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD).Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment?Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.Recent advances in COPD disease management with fixed-dose long-acting combination therapies.Formoterol fumarate inhalation solution (Perforomist) for COPD.Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells.Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist.PGE 2 desensitizes β -agonist effect on human lung fibroblast-mediated collagen gel contraction through upregulating PDE4.Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
P2860
Q24201828-75C58AC5-64CD-40CD-AC1B-5963EF0E26C0Q30480789-48C9BF09-25C7-4108-9E36-450EC1E9CBB5Q33966001-94D8DC75-5527-4CF6-8704-B250DB9D4063Q34039712-BED5E18D-6723-4FCE-AF83-0B0662F134E8Q34075548-D6020F33-9DA8-413A-ABCC-582134FE9862Q34590657-DEC9FF56-8219-4C99-A204-572E1B4CE643Q34642515-58E57A40-EB31-4BBD-9722-91F2AC3E39ECQ34834664-960E0BDE-B155-4E06-BCE5-C69DBAB84660Q35164693-BC6D1700-D040-46D7-A218-EC57AB2FF25DQ35201031-23B2E355-EDE7-4501-B032-9D41EE67BB48Q35627824-F4C854FF-8AF6-4881-A4B4-2F9A0CCA059FQ35968315-B0EBE7BF-794B-4B2B-ACEA-962743A413FEQ36203144-3307D5E9-AF54-4D30-8DDB-C932626F0F06Q36225454-6FFA334C-4D22-4DD1-A114-ECD590DE806AQ36301610-75EC38F1-B575-4FD9-8321-E40DCB0A76BDQ36389519-4288B1C2-E51F-46EB-A19E-591811BD91E0Q36438669-FCDFCC53-1E3C-4849-8800-EDAFBB95C8ACQ36695412-5ABD6539-A7EC-4B16-8714-474E3C145EF7Q36787296-CC29023F-64F8-4A73-9992-9845E386EE0BQ36956720-0D25C1E1-A6C8-4237-B814-00398F09E295Q37017344-6E02DE4D-9EE3-4A00-87C1-8AEBDF65C0ACQ37018887-6D60FCDB-B128-48B9-8D2C-D0482F08307CQ37070307-868EA0E0-4DEE-4CCD-B9C2-37F9D52F0D4DQ37189382-EC50AF03-1C4D-4C4E-A0AC-A23DEF5AA1C6Q37614090-11673356-D7EB-44EA-8C3B-945D304229E8Q37636173-70488DA4-EA1D-4823-AD21-A240C93A03F9Q37807916-1478540B-372A-498C-A9E7-7F4F894980B4Q37814698-97A4AC43-41F9-485D-A9C7-0CB022F1BDF2Q37951672-9795B11F-F383-4CBA-972D-4F7290A69480Q38116969-7DDB65F1-BDF4-4239-B71C-290C0E19A8EAQ38204363-26E18E30-39F7-4FC9-B756-1C8BB9B910B0Q38209841-78202BE2-F2EB-4558-B052-A779D88B43FBQ39317855-A8AA748B-096F-4291-A798-79D81D3BD95FQ39710234-5A2EA6F3-9EC2-4B3C-A868-8AA70686418AQ39721900-9B1FF655-6569-451E-94C5-A954033DA6C5Q39920199-13CB18CA-E762-4F11-9DFC-3C4B0D320DFFQ40136175-557CC8F7-FFA1-4369-A3AA-F56D37889111Q40628931-D8B63D40-F75A-45AE-BD26-C12C9C970BB0Q42921516-5942E47C-55D3-4BF3-9464-68C0F9B2101AQ44121414-56BDF387-1D0B-47B1-B24E-32C89010D970
P2860
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Alternative mechanisms for long-acting beta
@nl
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@ast
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@en
type
label
Alternative mechanisms for long-acting beta
@nl
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@ast
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@en
prefLabel
Alternative mechanisms for long-acting beta
@nl
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@ast
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@en
P356
P1433
P1476
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.
@en
P2093
P304
P356
10.1378/CHEST.120.1.258
P407
P577
2001-07-01T00:00:00Z